Helus Pharma is a pre-revenue biotechnology company with quality at 1.2/10, negative free cash flow and 254% implied volatility, so any upside to the $12.48 technical resistance (39.3%) comes with high binary and funding risk ahead of earnings in 4 days.
Thesis pillars
- Cash Burning Weak Fundamentals→Stable
- Pre Revenue Status↓Deteriorating
- Earnings Miss Pattern↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 8, 2026
Helus Pharma Inc. (HELP) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $8.96: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: Below-average business quality; Negative price momentum.
Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder;... Read more
Sell if holding. Engine safety override at $8.96: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.5/10, moderate confidence.
Passes 5/8 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and earnings proximity 3d<=7d. Suitability: speculative.
Recent developments
updated Nov 3, 2026Recent Developments — Helus Pharma Inc.
Latest news
- NEWS Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference — fiscal.ai Nov 3, 2026
- NEWS Insider Cluster Buying Reported at Helus Pharma Inc. — fiscal.ai Nov 2, 2026 positive
- NEWS 'New Bill In Congress Would Dramatically Overhaul How The Federal Government Classifies Drugs While Legalizing Marijuana — benzinga Oct 29, 2026 neutral
- NEWS Helus Pharma Announces Co-Founders' Transition from Executive Leadership — fiscal.ai Oct 27, 2026 negative
- NEWS Helus Pharma Appoints Mark Lawson As Board Chair, Effective Immediately — benzinga Oct 27, 2026 neutral
Latest item Nov 3, 2026 · Generated 2026-11-09T12:08:23Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $8.96: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $8.33. Score 4.5/10, moderate confidence.
Resistance target: $12.48 (+39.3% upside). Prior stop was $8.33. Stop-loss: $8.33.
DATA_ISSUE: analyst_target_implausible (raw $41.13 vs price $8.96 — ratio 4.6×). Rejected, falling back to technical TP.; Quality below floor (1.2 < 4.0).
Helus Pharma Inc. trades at a P/E of N/A (forward -5.1). TrendMatrix value score: 5.0/10. Verdict: Sell.
7 analysts rate HELP, with a consensus score of 4.1/5. 10 analysts publish price targets averaging $41.
What does Helus Pharma Inc. do?Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat...
Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company's preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluate HLP003 for the adjunctive treatment of major depressive disorder; and Osmind for mental health treatments. It operates in Canada, the United States, the United Kingdom, and Ireland. The company was formerly known as Cybin Inc. and changed its name to Helus Pharma Inc. in October 2026. Helus Pharma Inc. was founded in 2019 and is headquartered in Toronto, Canada.